$13.16
-0.14[-1.05%]
At close: Apr 15
$13.16
0[0.00%]
After Hours: 4:30PM EDT
Teva Pharmaceutical Indus
(NYSE:TEVA)Teva Pharmaceutical Indus Stock (NYSE:TEVA), Analyst Ratings, Price Targets, Predictions
Teva Pharmaceutical Industries Ltd has a consensus price target of $10.4, established from looking at the 34 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Piper Sandler, and Goldman Sachs on March 8, 2024, February 12, 2024, and February 5, 2024. With an average price target of $14.67 between JP Morgan, Piper Sandler, and Goldman Sachs, there's an implied 11.45% upside for Teva Pharmaceutical Industries Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Piper Sandler
Goldman Sachs
Barclays
Jefferies
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Teva Pharmaceutical Indus
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/08/2024 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | 6.38% | JP Morgan | Chris Schott | → $14 | Upgrade | Underweight → Neutral | Get Alert |
| 02/12/2024 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | 44.38% | Piper Sandler | David Amsellem | $12 → $19 | Upgrade | Neutral → Overweight | Get Alert |
| 02/05/2024 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -16.41% | Goldman Sachs | Nathan Rich | $10 → $11 | Maintains | Neutral | Get Alert |
| 02/05/2024 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | 29.18% | Barclays | Balaji Prasad | $15 → $17 | Maintains | Overweight | Get Alert |
| 01/29/2024 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | 13.98% | Barclays | Balaji Prasad | $14 → $15 | Maintains | Overweight | Get Alert |
| 01/23/2024 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | 6.38% | Jefferies | Glen Santangelo | $10 → $14 | Upgrade | Hold → Buy | Get Alert |
| 01/03/2024 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -8.81% | Piper Sandler | David Amsellem | $8 → $12 | Upgrade | Underweight → Neutral | Get Alert |
| 12/18/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -1.22% | HSBC | Rajesh Kumar | → $13 | Initiates | → Buy | Get Alert |
| 11/27/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -1.22% | UBS | Ashwani Verma | $11 → $13 | Upgrade | Neutral → Buy | Get Alert |
| 09/20/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -16.41% | UBS | Ashwani Verma | $8 → $11 | Maintains | Neutral | Get Alert |
| 09/08/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -1.22% | B of A Securities | Jason Gerberry | $12 → $13 | Maintains | Buy | Get Alert |
| 07/06/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -39.21% | UBS | Ashwani Verma | $7 → $8 | Upgrade | Sell → Neutral | Get Alert |
| 05/25/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -24.01% | Morgan Stanley | Thibault Boutherin | → $10 | Initiates | → Equal-Weight | Get Alert |
| 05/18/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | — | Evercore ISI Group | Umer Raffat | — | Upgrade | In-Line → Outperform | Get Alert |
| 05/11/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -16.41% | B of A Securities | Jason Gerberry | $13 → $11 | Maintains | Buy | Get Alert |
| 02/09/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | 6.38% | Barclays | Balaji Prasad | $13 → $14 | Maintains | Overweight | Get Alert |
| 01/19/2023 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -8.81% | Jefferies | Glen Santangelo | $10 → $12 | Downgrade | Buy → Hold | Get Alert |
| 11/23/2022 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -46.81% | Piper Sandler | David Amsellem | $8 → $7 | Maintains | Underweight | Get Alert |
| 11/14/2022 | TEVA | Buy Now | Teva Pharmaceutical Indus | $13.16 | -24.01% | JP Morgan | Chris Schott | $11 → $10 | Downgrade | Neutral → Underweight | Get Alert |
FAQ
What is the target price for Teva Pharmaceutical Indus (TEVA)?
The latest price target for Teva Pharmaceutical Indus (NYSE: TEVA) was reported by JP Morgan on March 8, 2024. The analyst firm set a price target for $14.00 expecting TEVA to rise to within 12 months (a possible 6.38% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Teva Pharmaceutical Indus (TEVA)?
The latest analyst rating for Teva Pharmaceutical Indus (NYSE: TEVA) was provided by JP Morgan, and Teva Pharmaceutical Indus upgraded their neutral rating.
When was the last upgrade for Teva Pharmaceutical Indus (TEVA)?
The last upgrade for Teva Pharmaceutical Industries Ltd happened on March 8, 2024 when JP Morgan raised their price target to $14. JP Morgan previously had an underweight for Teva Pharmaceutical Industries Ltd.
When was the last downgrade for Teva Pharmaceutical Indus (TEVA)?
The last downgrade for Teva Pharmaceutical Industries Ltd happened on January 19, 2023 when Jefferies changed their price target from $10 to $12 for Teva Pharmaceutical Industries Ltd.
When is the next analyst rating going to be posted or updated for Teva Pharmaceutical Indus (TEVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Teva Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Teva Pharmaceutical Indus was filed on March 8, 2024 so you should expect the next rating to be made available sometime around March 8, 2025.
Is the Analyst Rating Teva Pharmaceutical Indus (TEVA) correct?
While ratings are subjective and will change, the latest Teva Pharmaceutical Indus (TEVA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Teva Pharmaceutical Indus (TEVA) is trading at is $13.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.